文献速递青光眼

青光眼活动受限:剑桥青光眼视功能测试的客观评估

Activity Limitation in Glaucoma: Objective Assessment by the Cambridge Glaucoma Visual Function Test.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2016-01-01

这项横断面研究纳入70例青光眼患者和14名对照,评估计算机化剑桥青光眼视功能测试(CGVFT)的心理测量学特性。经Rasch分析,139个试行条目中59个拟合良好;CGVFT评分在对照与轻、中、重度青光眼间递增(P<0.001),与GAL-9、VFQUI相关,汇聚效度良好,分歧效度欠佳。作者认为该测试可能使青光眼患者、照护者、医疗服务提供者和政策制定者受益。

要点

  • CGVFT为计算机化视觉挑战测试,用于客观评估青光眼相关活动受限。
  • CGVFT评分在对照与轻、中、重度青光眼间递增,提示标准效度良好。
  • CGVFT与GAL-9(r=0.455,P<0.001)、VFQUI(r=0.399,P=0.005)相关,汇聚效度良好。

核心结论

  • CGVFT是一种对青光眼患者队列实施的计算机化视觉挑战测试,可能使青光眼患者、照护者、医疗服务提供者和政策制定者受益,并提高对青光眼所致活动受限的认识。

研究设计与样本

  • 横断面研究,纳入70例青光眼患者和14名对照,平均年龄69.0 ± 10.2岁,49名(58.3%)为男性,全部接受CGVFT测试。
  • 采用Rasch分析及标准效度、汇聚效度和分歧效度检验评估CGVFT的心理测量学特性,并用回归模型确定CGVFT个体测量值的预测因素。

主要发现

  • 139个试行CGVFT条目中59个对Rasch模型拟合可接受,精度可接受(个体分离指数2.13),靶向性可接受。
  • CGVFT个体测量值(logit)评分在对照(-0.20 ± 0.08)与轻度(-0.15 ± 0.08)、中度(-0.13 ± 0.10)、重度(-0.05 ± 0.10)青光眼患者间递增(ANOVA,P < 0.001),提示标准效度良好。
  • CGVFT与GAL-9个体测量值相关系数为0.455(P < 0.001),与VFQUI个体测量值相关系数为0.399(P = 0.005),提示汇聚效度良好;分歧效度欠佳。
  • 多变量分析中,较好的眼平均偏差较低和年龄较大与CGVFT个体测量值变差相关(P ≤ 0.001)。

关键数值与推荐

  • CGVFT评分:对照-0.20 ± 0.08,轻度青光眼-0.15 ± 0.08,中度-0.13 ± 0.10,重度-0.05 ± 0.10(ANOVA,P < 0.001)。
  • CGVFT与GAL-9相关系数0.455(P < 0.001),与VFQUI相关系数0.399(P = 0.005)。
  • 个体分离指数2.13;139个试行条目中59个拟合可接受。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 分歧效度欠佳。
  • 作者结论使用「may benefit」表述,未给出确定性推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We design and evaluate a computer-based objective simulation of activity limitation related to glaucoma. METHODS: A cross-sectional study was performed involving 70 glaucoma patients and 14 controls. Mean age was 69.0 ± 10.2 years; 49 (58.3%) were male. The Cambridge Glaucoma Visual Function Test (CGVFT) was administered to all participants. Rasch analysis and criterion, convergent, and divergent validity tests assessed the psychometric properties of the CGVFT. Regression modeling was used to determine factors predictive of CGVFT person measures. Sociodemographic information, better and worse eye visual field parameters, visual acuity, contrast sensitivity, and the Rasch-analyzed Glaucoma Activity Limitation-9 (GAL-9) and Visual Function Questionnaire Utility Index (VFQUI) questionnaire responses were recorded. RESULTS: From 139 pilot CGVFT items, 59 had acceptable fit to the Rasch model, with acceptable precision (person separation index, 2.13) and targeting. Cambridge Glaucoma Visual Function Test person measure (logit) scores increased between controls (-0.20 ± 0.08) and patients with mild (-0.15 ± 0.08), moderate (-0.13 ± 0.10), and severe (-0.05 ± 0.10) glaucoma (P < 0.001, ANOVA) indicating good criterion validity. Correlation coefficients of 0.455 (P < 0.001) between CGVFT and GAL-9 person measures and 0.399 (P = 0.005) between CGVFT and VFQUI person measures demonstrated convergent validity. Divergent validity was suboptimal. On multivariable analysis, lower better eye mean deviation and greater age were associated with worsening CGVFT person measures (P ≤ 0.001). CONCLUSIONS: The CGVFT is a computerized visual challenge test administered to a cohort of glaucoma patients. It may benefit glaucoma patients, careers, health care providers, and policy makers, providing increased awareness of activity limitation due to glaucoma.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Skalicky SE, McAlinden C, Khatib T, et al. Activity Limitation in Glaucoma: Objective Assessment by the Cambridge Glaucoma Visual Function Test. Invest Ophthalmol Vis Sci. 2016. PMID: 27835712. doi:10.1167/iovs.16-19458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。